$39.6 Million is the total value of CAXTON CORP's 15 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 11.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SVRA | SAVARA INC | $13,448,274 | +25.8% | 6,896,551 | 0.0% | 33.97% | +24.4% | |
| XERIS BIOPHARMA HOLDINGS INC | $9,843,616 | +22.6% | 6,039,028 | 0.0% | 24.86% | +21.2% | ||
| SPY | SPDR S&P 500 ETF TRtr unit | $6,528,542 | +7.0% | 15,947 | 0.0% | 16.49% | +5.9% | |
| RZLT | REZOLUTE INC | $2,694,061 | -7.2% | 1,403,157 | 0.0% | 6.80% | -8.3% | |
| XOP | SPDR SER TRs&p oilgas exp | $2,232,825 | -6.1% | 17,500 | 0.0% | 5.64% | -7.1% | |
| VECT | Buy | VECTIVBIO HLDG AG | $1,345,549 | -0.0% | 156,651 | +0.3% | 3.40% | -1.1% |
| AMLP | ALPS ETF TRalerian mlp | $1,140,175 | +1.5% | 29,500 | 0.0% | 2.88% | +0.4% | |
| MTEM | MOLECULAR TEMPLATES INC | $779,931 | +15.8% | 2,052,991 | 0.0% | 1.97% | +14.5% | |
| CMPX | Buy | COMPASS THERAPEUTICS INC | $675,451 | -36.4% | 211,740 | +0.3% | 1.71% | -37.1% |
| ALLK | Buy | ALLAKOS INC | $385,073 | +150.3% | 86,533 | +373.6% | 0.97% | +147.6% |
| CABA | Sell | CABALETTA BIO INC | $335,602 | -57.2% | 40,581 | -52.1% | 0.85% | -57.6% |
| ELEV | ELEVATION ONCOLOGY INC | $129,815 | +100.3% | 68,324 | 0.0% | 0.33% | +97.6% | |
| NEWAMSTERDAM PHARMA COMPANY*w exp 11/22/202 | $40,533 | +127.8% | 21,333 | 0.0% | 0.10% | +126.7% | ||
| BTWNW | BRIDGETOWN HOLDINGS LTD*w exp 09/30/202 | $6,970 | +49.2% | 39,773 | 0.0% | 0.02% | +50.0% | |
| LANVIN GROUP HOLDINGS LIMITE*w exp 01/14/202 | $4,500 | +19.2% | 12,000 | 0.0% | 0.01% | +10.0% | ||
| Exit | ARCELLX INC | $0 | – | -36,302 | -100.0% | -2.87% | – | |
| SCYX | Exit | SCYNEXIS INC | $0 | – | -1,723,947 | -100.0% | -6.87% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MOLECULAR TEMPLATES INC | 24 | Q2 2023 | 30.7% |
| STRONGBRIDGE BIOPHARMA PLC | 22 | Q3 2021 | 73.1% |
| GARRISON CAP INC | 18 | Q3 2020 | 9.9% |
| BERKSHIRE HATHAWAY INC DEL | 17 | Q3 2019 | 5.8% |
| EIGER BIOPHARMACEUTICALS INC | 17 | Q3 2022 | 1.7% |
| AGILE THERAPEUTICS INC | 16 | Q1 2018 | 55.5% |
| KALA PHARNACEUTICALS INC | 16 | Q4 2021 | 17.6% |
| CM FIN INC | 16 | Q1 2019 | 7.8% |
| SYNTA PHARMACEUTICALS CORP | 15 | Q2 2016 | 99.9% |
| CTI BIOPHARMA CORP | 14 | Q4 2021 | 8.7% |
View CAXTON CORP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Addex Therapeutics Ltd. | February 14, 2023 | 718,849 | 0.9% |
| Cardiff Oncology, Inc. | February 14, 2023 | 983,607 | 2.2% |
| Rezolute, Inc. | February 14, 2023 | 1,860,518 | 5.0% |
| Xeris Biopharma Holdings, Inc. | February 14, 2023 | 5,973,324 | 4.4% |
| CTI BIOPHARMA CORP | February 14, 2022 | 2,239,300 | 2.3% |
| Sierra Oncology, Inc. | February 14, 2022 | 1,119,322 | 7.0% |
| Strongbridge Biopharma plcSold out | January 05, 2022 | 0 | 0.0% |
| SUNESIS PHARMACEUTICALS INCSold out | February 16, 2021 | 0 | 0.0% |
| Alcentra Capital Corp | February 14, 2020 | 1,005,000 | 7.8% |
| Garrison Capital Inc. | February 14, 2020 | 1,223,096 | 7.6% |
View CAXTON CORP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
View CAXTON CORP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.